BR0311539A - Increased release of a nucleic acid construct in vivo by the poly-l-glutamate ("plg") system - Google Patents
Increased release of a nucleic acid construct in vivo by the poly-l-glutamate ("plg") systemInfo
- Publication number
- BR0311539A BR0311539A BR0311539-9A BR0311539A BR0311539A BR 0311539 A BR0311539 A BR 0311539A BR 0311539 A BR0311539 A BR 0311539A BR 0311539 A BR0311539 A BR 0311539A
- Authority
- BR
- Brazil
- Prior art keywords
- plg
- glutamate
- dna
- poly
- plasmid dna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
"LIBERAçãO AUMENTADA DE UM CONSTRUCTO DE áCIDO NUCLéICO IN VIVO PELO SISTEMA DE POLI-L-GLUTAMATO ('PLG')". DNA plasmídeo liberado por injeção / eletroporação para o músculo do esqueleto pode ser expresso, e níveis fisiológicos de transgene podem ser obtidos na circulação. Não obstante, estabilização de DNA nu pode ser requerida e necessária em alguns casos, como estocagem prolongada em diferentes temperaturas antes de utilização, injeção em um grande número de animais, etc. é imperativo que o composto associado não seja tóxico para as células (por exemplo, células de músculo) ou cause ruptura de DNA plasmídeo. Pode ser preferível para o DNA revestido ter uma tomada similar ou aumentada nas células alvo. Compostos poli-L-glutamato de baixo peso molecular têm todas as propriedades desejadas. Foi determinado que a razão mol / mol de DNA/PLG é a concentração ótima para aplicações terapêuticas de gene para o músculo de esqueleto, resultando em aumentada expressão do transgene, sem dano para o tecido alvo. Além disso, estabilização de DNA plasmídeo por PLG nunca foi observada ou descrita na literatura."INCREASED RELEASE OF IN VIVO NUCLEIC ACID CONSTRUCTION BY THE POLY-L-GLUTAMATE ('PLG') SYSTEM". Plasmid DNA released by injection / electroporation into the skeletal muscle can be expressed, and physiological levels of transgene can be obtained in the circulation. However, bare DNA stabilization may be required and necessary in some cases, such as prolonged storage at different temperatures before use, injection into a large number of animals, etc. It is imperative that the associated compound be non-toxic to cells (e.g., muscle cells) or cause plasmid DNA disruption. It may be preferable for the coated DNA to have a similar or increased uptake in the target cells. Low molecular weight poly-L-glutamate compounds have all the desired properties. It has been determined that the mol / mol ratio of DNA / PLG is the optimal concentration for therapeutic gene applications for skeletal muscle, resulting in increased transgene expression without damage to the target tissue. Moreover, plasmid DNA stabilization by PLG has never been observed or described in the literature.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15667002A | 2002-05-28 | 2002-05-28 | |
| US10/395,709 US20040014645A1 (en) | 2002-05-28 | 2003-03-24 | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
| PCT/US2003/016541 WO2003099341A1 (en) | 2002-05-28 | 2003-05-23 | Increased delivery of a nucleic acid constrtuct in vivo by the poly-l-glutamate (plg) system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0311539A true BR0311539A (en) | 2005-10-25 |
Family
ID=29586320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0311539-9A BR0311539A (en) | 2002-05-28 | 2003-05-23 | Increased release of a nucleic acid construct in vivo by the poly-l-glutamate ("plg") system |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1513559A4 (en) |
| CN (1) | CN1662261A (en) |
| AU (1) | AU2003273142A1 (en) |
| BR (1) | BR0311539A (en) |
| CA (1) | CA2485976A1 (en) |
| MX (1) | MXPA04011766A (en) |
| WO (1) | WO2003099341A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005089810A1 (en) * | 2004-03-22 | 2005-09-29 | Kansai Technology Licensing Organization Co., Ltd. | Method of inducing bone by transferring human osteogenetic factor gene with the use of electroporation method |
| ATE413890T1 (en) * | 2004-07-23 | 2008-11-15 | Advisys Inc | GROWTH HORMONE RELEASING HORMONE ENHANCES THE VACCINE-INDUCED IMMUNE RESPONSE |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020047096A (en) * | 1999-07-26 | 2002-06-21 | 크로커 사무엘 에스 | Super-active porcine growth hormone releasing hormone analog |
| WO2001066149A2 (en) * | 2000-03-03 | 2001-09-13 | Valentis, Inc. | Nucleic acid formulations for gene delivery and methods of use |
| CA2469310C (en) * | 2001-12-11 | 2013-01-29 | Advisys, Inc. | Plasmid mediated supplementation for treating chronically ill subjects |
-
2003
- 2003-05-23 WO PCT/US2003/016541 patent/WO2003099341A1/en not_active Application Discontinuation
- 2003-05-23 BR BR0311539-9A patent/BR0311539A/en not_active Application Discontinuation
- 2003-05-23 CA CA002485976A patent/CA2485976A1/en not_active Abandoned
- 2003-05-23 CN CN 03814625 patent/CN1662261A/en active Pending
- 2003-05-23 AU AU2003273142A patent/AU2003273142A1/en not_active Abandoned
- 2003-05-23 EP EP03741818A patent/EP1513559A4/en not_active Withdrawn
- 2003-05-23 MX MXPA04011766A patent/MXPA04011766A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1513559A1 (en) | 2005-03-16 |
| MXPA04011766A (en) | 2005-03-31 |
| WO2003099341A1 (en) | 2003-12-04 |
| CA2485976A1 (en) | 2003-12-04 |
| EP1513559A4 (en) | 2006-01-18 |
| CN1662261A (en) | 2005-08-31 |
| AU2003273142A1 (en) | 2003-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0515553A (en) | stable liquid plasmid DNA formulations | |
| BR112013004917A2 (en) | systemic allogeneic stem cell therapies for treating diseases in animals. | |
| WO2007035213A3 (en) | Transgenic ungulates expressing ctla4-ig and uses thereof | |
| ES2607648T3 (en) | Prevention of the synthesis of cellular DNA and poliopédido of inhibition of the cellular proliferation and use of this | |
| BR112015012872A2 (en) | aqueous suspension nematicidal concentrate compositions | |
| NO20084738L (en) | Compounds and Methods for Modulating the Expression of PCSK9 | |
| BR112015030142A2 (en) | proton binding polymers for oral administration | |
| WO2008131129A3 (en) | Nucleic acid microparticles for pulmonary delivery | |
| BRPI0513206A (en) | controlled release composition for the treatment of domestic bees, method for the control of parasitic mites on domestic bees, kit for the treatment of parasitic mites on domestic bees, and method for producing a non-flowable polymeric gel for controlled release of acid vapors formic | |
| BRPI0509271A (en) | gastro-resistant pharmaceutical dosage forms comprising n- (2- (2-phthalimideethoxy) -acetyl-1-alanyl-d-glutamic acid (lk-4 23) | |
| Zhou et al. | Comparative analysis of the gut microbial communities of the Eurasian kestrel (Falco tinnunculus) at different developmental stages | |
| Early et al. | Repeat oral dose toxicity studies of melamine in rats and monkeys | |
| Eme et al. | Daily, repeating fluctuations in embryonic incubation temperature alter metabolism and growth of Lake whitefish (Coregonus clupeaformis) | |
| Sharp | The human genome and sport, including epigenetics, gene doping, and athleticogenomics | |
| BR0311539A (en) | Increased release of a nucleic acid construct in vivo by the poly-l-glutamate ("plg") system | |
| Grosiak et al. | Age-related changes in the thermoregulatory properties in bank voles from a selection experiment | |
| ES2251307A1 (en) | Solution for the indefinite maintenance of nucleic acids in the cell of origin thereof | |
| Wang et al. | Methodologies for inducing cardiac injury and assaying regeneration in adult zebrafish | |
| ATE538779T1 (en) | MENTHOL CONTAINING PREPARATION | |
| HRP20110459T1 (en) | Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas | |
| Gabrić et al. | Comparison between diode laser and conventional technique for soft tissue oral surgery: a pilot study | |
| DE60002603D1 (en) | PHOSPHORUS-CONTAINING DENDRIMERS AS TRANSFECTION AGENTS | |
| Rix et al. | Hypoxia-inducible factor-1α in Antarctic notothenioids contains a polyglutamine and glutamic acid insert that varies in length with phylogeny | |
| BRPI0615555A2 (en) | compositions and methods for the control of cupredoxin angiogenesis | |
| Nabinger et al. | Ecosystems services from natural grasslands:¿ it's possible to enhance them with more productivity? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |